🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT07519863
Recruiting Phase 2

The Effect of Dormicum-Ketamine Versus Dexmedetomidine on Emergence Delirium During Deep Sedation in Paediatric Burn Patients

NCT07519863 · tracked via the Priya Life Science Egypt tracker
Phase
Phase 2
Started
2025-11-20
Last updated
2026-04-09

Condition(s) studied

Emergence Delirium in Pediatric Anesthesia

Investigational drug(s) / intervention(s)

Midazolam + KetamineAll Midazolam trials (60) →All Ketamine trials (45) →Dexmedetomidine (DEX) →

Midazolam + Ketamine: Participants will receive intravenous midazolam (0.05 mg/kg) combined with ketamine (1 mg/kg). Supplemental ketamine doses (0.5 mg/kg) will be administered as needed to maintain adequate deep sedation during burn-related procedures.

Dexmedetomidine (DEX): Participants will receive intravenous dexmedetomidine (loading dose 1 mcg/kg over 15 minutes, followed by infusion 0.5-1 mcg/kg/hour) adjusted to maintain adequate deep sedation during burn-related procedures.

Study summary

The aim of this study is to compare the effects of dormicum-ketamine versus dexmedetomidine on postoperative emergence delirium in pediatric patients undergoing deep sedation for burn-related procedures

Eligibility

Sex
ALL
Min age
3 Years
Max age
16 Years
Healthy volunteers
No
Inclusion Criteria: * Age from 3 to 16 years * Both sexes * Patients classified as American Society of Anesthesiologists (ASA) Physical -Status I-II * Patients scheduled for elective burn-related procedures (e.g., burn dressing changes or minor interventions) Exclusion Criteria: * Refusal or inability to provide written informed consent from parent or legal guardian * Known allergy or hypersensitivity to any of the study medications (midazolam, ketamine, or dexmedetomidine) * Presence of hepatic dysfunction * Presence of renal dysfunction * Presence of immunological or hematological disorders * History of epilepsy, developmental delay (mental retardation), or neurological deficits * Patients receiving or requiring high doses of inotropes and/or vasopressors intraoperatively or postoperatively * Preoperative hemodynamic instability, defined as uncontrolled hypertension, hypotension, or bradycardia

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Ain Shams University Cairo Egypt Recruiting

More Ain Shams University trials in Egypt

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07519863 on ClinicalTrials.gov ↗ ← All trials in Egypt